检索结果-南通市图书馆

Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma

World Journal of Gastroenterology 2011年第45期17卷 4952-4959页

作者： Yasunori Minami Masatoshi Kudo Department of Gastroen-terology and Hepatology Kinki University School of Medicine

Local ablative techniques-percutaneous ethanol injection, microwave coagulation therapy and radiofrequency ablation (RFA)-have been developed to treat unresectable hepatocellular carcinoma (HCC). The success rate of percutaneous ablation therapy for HCC depends on correct targeting of the tumor via an imaging technique. However, probe insertion often is not completely accurate for small HCC nodules, which are poorly def ined on conventional B-mode ultrasound (US) alone. Thus, multiple sessions of ablation therapy are frequently required in diffi cult cases. By means of two breakthroughs in US technology, harmonic imaging and the development of second-generation contrast agents, dynamic contrast-enhanced harmonic US imaging with an intravenous contrast agent can depict tumor vascularity sensitively and accurately, and is able to evaluate small hypervascular HCCs even when B-mode US cannot adequately characterize the tumors. Therefore, dynamic contrast-enhanced US can facilitate RFA electrode placement in hypervascular HCC, which is poorly depicted by B-mode US. The use of dynamic contrast-enhanced US guidance in ablation therapy for liver cancer is an effi cient approach. Here, we present an overview of the current status of dynamic contrast-enhanced US-guided ablation therapy, and summarize the current indications and outcomes of reported clinical use in comparison with that of other modalities.

关键词： dynamic contrast-enhanced ultrasound Hepatocellular carcinoma Percutaneous ethanol injection Radiofrequency ablation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Quantitative evaluation of CA4P early efficacy in tumor model with dynamic contrast-enhanced ultrasound

Quantitative evaluation of CA4P early efficacy in tumor mode...

引用

中国超声医学工程学会第十四届全国超声心动图学术会议

作者： Qiaofeng Jin Yihan Chen Pingyu Zhang Jinfen Liu Jing Wang Yali Yang Qing Lv Mingxing Xie Department of ultrasound Union HospitalTongji Medical CollegeHuazhong University of Science and Technology Hubei Province Key Laboratory of Molecular Imaging

Objective:This study was to quantify both central and peripheral tumor perfusion with contrast-enhanced ultrasound(CEUS) in the evaluation of early tumor response to anti-vascular *** and Method:44 mice bearing with colon cancer were administrated with Combretastatin A4 phosphate(CA4 P) at 100 mg/*** was performed on treated groups(at 2,12,48 hours after the treatment) and untreated group(Oh).Time-intensity curves(TICs) were derived from regions of interest(ROI) in center(ROI) and peripheral(ROI) region of each tumor CEUS *** perfusion parameters including maximum intensity(IMAX),time to peak(TTP) and quality of fit(QOF)were calculated from TIC and normalized with respect to perfusion of adjacent *** analysis was conducted to evaluate tumor necrosis area%,microvascular density(MVD) and tumor ***:Significant decrease of IMAX in ROI was noticed from 2 hours after CA4 P therapy(P<0.01) and increase at 48 hours,but IMAX in ROI decreased significantly only at 12 hours(P<0.01).There were significant differences of TTP between 2 hours and other time points in both ROIcenter and ROIperiphery(P<0.01).After CA4 P treatment,vessel density decreased in the center of tumor from 2 hours,but not in the tumor *** decrease of tumor perfusion(Hoechst 33342 staining) and vascular perfusion(FITC-lectin staining) were seen at 2,12 and 48 hours after CA4 P treatment The IMAX were statistically positive correlated with Hoechst 33342 staining(r=0.77,P<0.001),compared with weaker correlation with MVD(r= 0.67,P<0.001)Conclusion:CEUS patterns and parameters are more closely correlated with tumor perfusion *** CEUS for quantification of tumor perfusion could be used for early detection of cancer response to anti-vascular treatment

关键词： dynamic contrast-enhanced ultrasound antiangiogenic treatments,perfusion parameters combretastatin A4 phosphate vascular disrupting agent

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study

引用

Cancer Communications 2018年第1期38卷 701-713页

作者： Qiuyan Chen Linquan Tang Na Liu Feng Han Ling Guo Shanshan Guo Jianwei Wang Huai Liu Yanfang Ye Lu Zhang Liting Liu Pan Wang Yingqin Li Qingmei He Xiaoqun Yang Qingnan Tang Yang Li YuJing Liang XueSong Sun Chuanmiao Xie Yunxian Mo Ying Guo Rui Sun Haoyuan Mo Kajia Cao Xiang Guo Musheng Zeng Haiqiang Mai Jun Ma State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer MedicineGuangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and TherapySun Yat-sen University Cancer CenterGuangzhou 510060P.R.China Department of Nasopharyngeal Carcinoma Sun Yat-sen University Cancer CenterGuangzhou 510060P.R.China Department of ultrasound Sun Yat-sen University Cancer CenterGuangzhou 510060P.R.China Department of Radiation Oncology Key Laboratory of Translational Radiation OncologyHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of MedicineCentral South UniversityChangsha 410013P.R.China Department of Science and Education Sun Yat-sen Memorial HospitalGuangzhou 510120P.R.China Department of Radiation Oncology The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou 510120P.R.China Department of Imaging Sun Yat-sen University Cancer CenterGuangzhou 510060P.R.China Department of Clinical Trial Center Sun Yat-sen University Cancer CenterGuangzhou 510060P.R.China Department of Radiation Oncology Sun Yat-sen University Cancer CenterGuangzhou 510060P.R.China

Background:Famitinib is a tyrosine kinase inhibitor against multiple targets,including vascular endothelial growth factor receptor 2/3,platelet-derived growth factor receptor,and stem cell factor receptor(c-kit).Previous studies have demonstrated anti-tumour activities of famitinib against a wide variety of advanced-stage solid *** aimed to determine the safety and efficacy of famitinib with concurrent chemoradiotherapy(CCRT)in patients with locoregionally advanced nasopharyngeal carcinoma(NPC).We also evaluated the feasibility of contrast-enhanced ultrasound(D-CEUS)as a predictor of early tumour response to famitinib and to correlate functional parameters with clinical ***:The trial was conducted in subjects with stage III or IVa-b NPC using a 3+3 design of escalating fami-tinib ***,subjects received 2 weeks of famitinib monotherapy followed by 7 weeks of famitinib plus CCRT.D-CEUS of the neck lymph nodes was performed at day 0,8 and 15 after famitinib was administered before starting concurrent *** points included safety,tolerability and anti-tumour ***:Twenty patients were enrolled(six each for 12.5,16.5 and 20 mg and two for 25 mg).Two patients in the 25 mg cohort developed dose-limiting toxicities,including grade 4 thrombocytopenia and grade 3 *** most common grade 3/4 adverse events were leukopenia,neutropenia and radiation mucositis.D-CEUS tests showed that more than 60%of patients achieved a perfusion parameter response after 2 weeks taking famitinib alone,and the parameter response was associated with disease *** the famitinib monotherapy stage,three patients(15%)showed partial *** complete response rate was 65%at the completion of treatment and 95%3 months after the treatment *** a median follow-up of 44 months,the 3-year progression-free survival(PFS)and distant metastasis-free survival were 70%and 75%,*** with a decrease of perfusion p

关键词： Nasopharyngeal carcinoma Famitinib Concurrent chemoradiotherapy Phase I dynamic contrast-enhanced ultrasound

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：